Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05350631
Other study ID # 8360
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 4, 2023
Est. completion date July 2024

Study information

Verified date October 2023
Source University Hospital, Strasbourg, France
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Approximately 2,200 cancers per year in France are diagnosed within the adolescents and young adults population (15-25 years old, AYA). The cancer plans and the INCA recommend support during and after cancer treatment, taking into account both medical and psycho-social specificities related to age (support care, school learning/training and professional integration, fertility preservation, therapeutic education, addictology, sexology...). In this context, AJA teams have been developed in which the Nurse Coordinators (IDEC) play a fundamental role. These Nurse Coordinators are available to young patients, their families and the professionals who accompany follow them in their therapeutic journey. Their main missions are to assess the specific needs of these young people and their loved ones, to inform, orient and participate in the coordination of their care by providing psychosocial and paramedical solutions to these young patients. The circular of 30/05/2016 on the coordinated regional organization of care for AJAs supports the development of connected health tools for AJAs. This population is adept to new technologies, social networks allowing them to continue to be informed and remain integrated to the outside world while helping them prepare for life after cancer. In this context, our team initiated the development of a digital application compatible for any cellphone OnKO-Tips&Tricks meeting these criteria of necessity with the company CAPCOD. We would want to move on to a validation stage by carrying out a national multicenter efficacy study in AJA mobile units by comparing two groups of patients: users/non-users of this digital tool on a main criterion of quality of life after using it for 6 months. As it should promote autonomy and integration into the care pathway as well as active participation in therapeutic education programs (TPE), these different items will be evaluated as secondary endpoints of our study


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date July 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 15 Years to 25 Years
Eligibility Inclusion Criteria: - Patient age = 15 years and = 25 years - Diagnosed with solid or blood cancers less than 1 month old or patient with relapsed cancer more than 5 years after completion of initial treatment - Follow-up at one of the participating study centers - Informed and signed consent from the patient and, if the subject is a minor, from the holders of parental authority - Inclusion in the study at the latest at the time of initiation of chemotherapy or radiotherapy - Patient agrees to 12-month post-inclusion follow-up - Patient agreeing to complete all study questionnaires - Patient with a cellphone capable of downloading the app (developed for all types of cellphones) - Affiliated to a social health insurance plan Exclusion Criteria: - Patient deprived of liberty by a judicial or administrative decision - Patient with protected person status - Patient who does not understand, speak or write French - Patient unable to understand the follow-up protocol according to the investigating physician or the IDEC of the AJA unit - Patient with a scheduled hospitalization of at least 5 weeks during study participation

Study Design


Related Conditions & MeSH terms


Intervention

Other:
OnKO-Tips&Tricks digital phone application
Using daily OnKO-Tips&Tricks digital phone application

Locations

Country Name City State
France Institut d'Hématologie et d'Oncologie Pédiatrique Lyon
France Assistance Publique - Hôpitaux de Marseille Marseille
France Hôpital enfant-adolescent Nantes
France CHU de Nice Hôpital Archet 2 Nice
France CHU Reims - Hôpital Maison Blanche Reims
France CHU Rennes Hôpital Sud Rennes
France Institut de Cancérologie de l'Ouest Saint-Herblain
France Hôpitaux Universitaires de Strasbourg Strasbourg
France Institut de Cancerologie Strasbourg Europe Strasbourg
France Institut Gustave Roussy Villejuif

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the efficacy of the OnKO-Tips&Tricks digital phone application on the psychosocial dimension of patients' quality of life Assessed using a psychosocial health score obtained by the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales questionnaire.
The PedsQL 4.0 Generic Core Scale contains 23 items that measures physical (eight items), emotional (five items), social (five items), and school (five items) functions. The Scale comprises parallel patient self-report and parent proxy-report formats. The items are reverse-scored and trans- formed to a 0-100 scale according to the instructions, and higher scores indicate a better HRQOL.
6 months of inclusion
Secondary Evaluate the efficacy of the OnKO-Tips&Tricks digital phone application on the psycho-social dimension of patients' quality of life Assessed using a psychosocial health score obtained from the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales questionnaire.
The PedsQL 4.0 Generic Core Scale contains 23 items that measures physical (eight items), emotional (five items), social (five items), and school (five items) functions. The Scale comprises parallel patient self-report and parent proxy-report formats. The items are reverse-scored and trans- formed to a 0-100 scale according to the instructions, and higher scores indicate a better HRQOL.
3 months and 12 months of inclusion
Secondary Evaluate the efficacy of the OnKO-Tips&Tricks digital phone application on patients' overall and physical quality of life Assessed using total Quality of Life and physical health subscore scores obtained from the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales questionnaire.
The PedsQL 4.0 Generic Core Scale contains 23 items that measures physical (eight items), emotional (five items), social (five items), and school (five items) functions. The Scale comprises parallel patient self-report and parent proxy-report formats. The items are reverse-scored and trans- formed to a 0-100 scale according to the instructions, and higher scores indicate a better HRQOL.
3 months, 6 months and 12 months of inclusion
Secondary Evaluate the impact on each patient's participation in a therapeutic education program (TPE) Rate of patients in the experimental and control groups who will participate in the proposed FTE program through study completion, an average of 1 year and 6 months
Secondary Evaluate the efficacy of the OnKO-Tips&Tricks digital phone application throughout the patient's care pathway assessed by the number of consultations, medical and paramedical, the number of outpatient management, the number of unscheduled hospitalizations, the number of listed side effects, and the number of phone contacts (text, calls) and emails initiated by the patient towards the IDEC. 3 months, 6 months and 12 months of inclusion
Secondary Assess patient satisfaction with the use of the OnKO-Tips&Tricks digital phone application using the MAUQ questionnaire Evaluated using the mHealth app usability questionnaire (MAUQ questionnaire). 6 and 12 months
Secondary Evaluate the adherence to the application in the experimental group Evaluated by collecting the number of uses of each feature Per week and per month through study completion, an average of 1 year and 6 months
Secondary Evaluate the efficacy of the OnKO-Tips&Tricks digital phone application on the quality of life of patients according to cancer pathology Comparative analysis of quality of life collection using the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales questionnaire taking into account the type of cancers: solid vs. blood cancer The PedsQL 4.0 Generic Core Scale contains 23 items that measures physical (eight items), emotional (five items), social (five items), and school (five items) functions. The Scale comprises parallel patient self-report and parent proxy-report formats. The items are reverse-scored and trans- formed to a 0-100 scale according to the instructions, and higher scores indicate a better HRQOL. 6 months of inclusion
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients